Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Food Scene
Community Directory
Community Service
Restaurant Guide
Rescue Me
Other
Specials
Entertainment Now
Spring Wellness
Home & Garden
Home Improvement
Home & Realty
Horizons
Outdoor Guide
Progress
Women
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Services
2022 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Adicet Bio, Inc.
Adicet Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress
March 15, 2023
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio to Participate in 2023 Jefferies Biotech on the Bay Summit
March 09, 2023
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
February 28, 2023
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio to Participate in a Fireside Chat at the 2023 Guggenheim Oncology Conference
February 01, 2023
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
January 31, 2023
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
December 30, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)
December 10, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio to Host Investor Webcast to Discuss Updated Clinical Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)
December 02, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
November 30, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio to Present at the Virtual JMP Securities Hematology and Oncology Summit
November 30, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Appoints Nancy Boman, M.D., Ph.D., as Senior Vice President and Chief Regulatory Officer
November 29, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Reports Third Quarter 2022 Financial Results and Provides Business Updates
November 08, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Showcases Preclinical Data for Four New Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
November 07, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Reports ASH Abstract Data from Ongoing ADI-001 Phase 1 Trial in Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)
November 03, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio to Present at the 2022 Jefferies London Healthcare Conference
November 01, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
October 31, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio to Present Preclinical Data from Allogeneic Gamma Delta T Cell Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
October 05, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
September 30, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio to Present at Upcoming Investor Conferences
September 07, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
August 31, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Reports Second Quarter 2022 Financial Results and Provides Business Updates
August 10, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio to Present at Upcoming Investor Conferences
August 01, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
July 29, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
July 01, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio to Present at Upcoming Investor Conferences
June 21, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Reports Emerging Data from ADI-001 Phase 1 Trial at the American Society of Clinical Oncology Annual Meeting
June 06, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
June 03, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Reports Positive Clinical Update from ADI-001 Phase 1 Trial in Relapsed/Refractory Non-Hodgkin’s Lymphoma (NHL)
May 26, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio to Present at Upcoming Investor Conferences
May 18, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Reports First Quarter 2022 Financial Results and Provides Business Updates
May 12, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.